Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Otenaproxesul and COVID-19 Data

<< Previous

Bullboard Posts

Next >>

Comment by Rarbar99on Aug 19, 2021 12:35pm

95 Views

Post# 33730859

RE:RE:RE:Otenaproxesul and COVID-19 Data

"It's not a serious issue."

That's why none of their insiders are buying even after a 70% drop. You people are such gullible fools it is absolutely hilarious.

The biggest purchase they made was the CEO, and he only bought $10K worth which is pennies in the grand scheme. If this was all FUD and an overreaction, the insiders would have bought hundreds of thousands, if not millions. Instead, they bought mere thousands. Most of them didn't even buy more than 2000 shares which is laughable at best.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading